{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:57:11Z","timestamp":1789750631694,"version":"4.0.1"},"reference-count":285,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Non-infectious uveitis and scleritis are significant causes of visual impairment, and currently available targeted and effective therapeutic options remain limited. Multiple immunologic pathways are currently under investigation and targeted therapeutics have the potential to change the treatment landscape and improve visual outcomes. This review synthesizes potential upcoming local and systemic treatments for non-infectious uveitis and scleritis with a focus on therapeutics with human data, noting those with the most promising evidence, and areas of gaps in research.<\/jats:p>","DOI":"10.3389\/fmed.2026.1846374","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:43:12Z","timestamp":1778823792000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging therapeutic targets in non-infectious uveitis and scleritis"],"prefix":"10.3389","volume":"13","author":[{"given":"Usanee","family":"Tungsattayathitthan","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Feinberg School of Medicine, Northwestern University","place":["Chicago, IL, United States"]},{"name":"Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University","place":["Bangkok, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra A.","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Feinberg School of Medicine, Northwestern University","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Janetos","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Feinberg School of Medicine, Northwestern University","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.preteyeres.2013.02.004","article-title":"Scleritis: Immunopathogenesis and molecular basis for therapy.","volume":"35","author":"Wakefield","year":"2013","journal-title":"Prog Retin Eye Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3109\/09273948.2013.863944","article-title":"Treatment of chronic, noninfectious, nonnecrotizing scleritis with tumor necrosis factor alpha inhibitors.","volume":"22","author":"Ragam","year":"2014","journal-title":"Ocul Immunol Inflamm."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2025.10.004","article-title":"Adalimumab versus conventional immunosuppression for uveitis (ADVISE) Trial.","author":"Jabs","year":"2025","journal-title":"Ophthalmology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1080\/09273948.2023.2263095","article-title":"Efficacy of TNF-alpha inhibitors to control inflammation and prevent secondary complications in non-infectious uveitis: a real-life experience from Switzerland.","volume":"32","author":"Fuchs","year":"2024","journal-title":"Ocul Immunol Inflamm."},{"key":"B6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s10067-016-3527-z","article-title":"The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases.","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1002\/art.22966","article-title":"NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort.","volume":"56","author":"Ar\u00f3stegui","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1136\/bjo.2006.0101477","article-title":"Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome.","volume":"91","author":"Teoh","year":"2007","journal-title":"Br J Ophthalmol."},{"key":"B10","first-page":"47","article-title":"Bilateral serous retinal detachment from neonatal-onset multisystemic inflammatory disorder.","volume":"102","author":"Statler","year":"2013","journal-title":"R I Med J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/ICB.0000000000000756","article-title":"Cryopyrin-associated periodic syndrome-associated uveitis and papillitiS.","volume":"15","author":"Ma","year":"2021","journal-title":"Retin Cases Brief Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.ajo.2023.11.014","article-title":"Bilateral scleritis at the onset of macrophage activation syndrome.","volume":"258","author":"Tarsia","year":"2024","journal-title":"Am J Ophthalmol."},{"key":"B13","first-page":"152","article-title":"Anakinra for resistant Beh\u00e7et uveitis: why not?","volume":"31","author":"Emmi","year":"2013","journal-title":"Clin Exp Rheumatol."},{"key":"B14","first-page":"S171","article-title":"Efficacy of anakinra in refractory Beh\u00e7et\u2019s disease sacroiliitis.","volume":"32","author":"Caso","year":"2014","journal-title":"Clin Exp Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/ijd.13337","article-title":"Long-term efficacy and safety of anakinra in a patient with Beh\u00e7et\u2019s disease and concomitant tuberculosis infection.","volume":"56","author":"Emmi","year":"2017","journal-title":"Int J Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra treatment in drug-resistant Behcet\u2019s disease: a case series.","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","article-title":"Efficacy and safety profile of anti-interleukin-1 treatment in Beh\u00e7et\u2019s disease: a multicenter retrospective study.","volume":"35","author":"Emmi","year":"2016","journal-title":"Clin Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/09273948.2018.1511810","article-title":"The presence of uveitis is associated with a sustained response to the interleukin (IL)-1 Inhibitors anakinra and canakinumab in Beh\u00e7et\u2019s disease.","volume":"28","author":"Fabiani","year":"2020","journal-title":"Ocul Immunol Inflamm."},{"key":"B19","doi-asserted-by":"publisher","first-page":"102152","DOI":"10.1016\/j.msard.2020.102152","article-title":"Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis.","volume":"42","author":"Lopalco","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ajo.2026.01.037","article-title":"Adalimumab, anakinra, and tocilizumab in patients with noninfectious uveitis: a multicenter randomized controlled trial.","volume":"285","author":"Saadoun","year":"2026","journal-title":"Am J Ophthalmol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/rheumatology\/kem052","article-title":"Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases.","volume":"46","author":"Botsios","year":"2007","journal-title":"Rheumatol Oxf Engl."},{"key":"B22","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/09273948.2017","article-title":"Anakinra in the treatment of patients with refractory scleritis: a pilot study.","volume":"26","author":"Bottin","year":"2018","journal-title":"Ocul Immunol Inflamm."},{"key":"B23","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1055\/a-1766-6739","article-title":"Intermediate uveitis in an HLA-B27-positive patient treated with upadacitinib.","volume":"239","author":"Schneider","year":"2022","journal-title":"Klin Monatsbl Augenheilkd."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-201383","article-title":"Canakinumab in a patient with juvenile Behcet\u2019s syndrome with refractory eye disease.","volume":"71","author":"Ugurlu","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/art.37776","article-title":"Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis.","volume":"65","author":"Simonini","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000358125","article-title":"Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Beh\u00e7et\u2019s disease: a case series.","volume":"228","author":"Vitale","year":"2014","journal-title":"Dermatol Basel Switz."},{"key":"B27","first-page":"S172","article-title":"Reply: anti-IL1 blocking agents in drug-resistant Beh\u00e7et\u2019s syndrome: our little case series.","volume":"32","author":"Emmi","year":"2014","journal-title":"Clin Exp Rheumatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12348-015-0065-9","article-title":"Successful resolution of stromal keratitis and uveitis using canakinumab in a patient with chronic infantile neurologic, cutaneous, and articular syndrome: a case study.","volume":"5","author":"Hirano","year":"2015","journal-title":"J Ophthalmic Inflamm Infect."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.3899\/jrheum.160064","article-title":"Canakinumab for childhood sight-threatening refractory uveitis: a case series.","volume":"43","author":"Brambilla","year":"2016","journal-title":"J Rheumatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1080\/09273948.2024.2317978","article-title":"Familial mediterranean fever-associated retinal vasculitis: a rare manifestation successfully managed with IL-1 pathway inhibitors.","volume":"32","author":"Anglada-Masferrer","year":"2024","journal-title":"Ocul Immunol Inflamm."},{"key":"B31","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","article-title":"Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet\u2019s disease: an open-label pilot study.","volume":"71","author":"G\u00fcl","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3109\/09273948.2015.1092558","article-title":"Safety and efficacy of gevokizumab in patients with Beh\u00e7et\u2019s disease uveitis: results of an exploratory phase 2 study.","volume":"25","author":"Tugal-Tutkun","year":"2017","journal-title":"Ocul Immunol Inflamm."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/09273948.2017.1421233","article-title":"Use of gevokizumab in patients with Beh\u00e7et\u2019s disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study.","volume":"26","author":"Tugal-Tutkun","year":"2018","journal-title":"Ocul Immunol Inflamm."},{"key":"B34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ajo.2016.09.017","article-title":"Gevokizumab in the treatment of autoimmune non-necrotizing anterior scleritis: results of a phase I\/II clinical trial.","volume":"172","author":"Knickelbein","year":"2016","journal-title":"Am J Ophthalmol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10067-018-4119-x","article-title":"Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study.","volume":"37","author":"Sota","year":"2018","journal-title":"Clin Rheumatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"116605","DOI":"10.1016\/j.bcp.2024.116605","article-title":"Interleukin-6 in non-infectious uveitis: Biology, experimentalevidence and treatment strategies.","volume":"230","author":"Yu","year":"2024","journal-title":"Biochem Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2147\/OPTH.S68595","article-title":"Targeting interleukin-6 for noninfectious uveitis.","volume":"9","author":"Lin","year":"2015","journal-title":"Clin Ophthalmol Auckl NZ."},{"key":"B38","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3109\/09273948.2011.606593","article-title":"Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis.","volume":"19","author":"Muselier","year":"2011","journal-title":"Ocul Immunol Inflamm."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.3899\/jrheum.120010","article-title":"Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?","volume":"39","author":"Tappeiner","year":"2012","journal-title":"J Rheumatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s10165-011-0497-5","article-title":"A case of Beh\u00e7et\u2019s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.","volume":"22","author":"Hirano","year":"2012","journal-title":"Mod Rheumatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"968180","DOI":"10.1155\/2012\/968180","article-title":"Refractory uveitis in patient with castleman disease successfully treated with tocilizumab.","volume":"2012","author":"Oshitari","year":"2012","journal-title":"Case Rep Ophthalmol Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00417-013-2466-5","article-title":"Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report.","volume":"252","author":"Ad\u00e1n","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3109\/09273948.2013.866254","article-title":"Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient.","volume":"22","author":"Tsang","year":"2014","journal-title":"Ocul Immunol Inflamm."},{"key":"B44","first-page":"S54","article-title":"Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review.","volume":"32","author":"Calvo-R\u00edo","year":"2014","journal-title":"Clin Exp Rheumatol."},{"key":"B45","first-page":"S75","article-title":"Tocilizumab in severe and refractory non-infectious uveitis.","volume":"32","author":"Papo","year":"2014","journal-title":"Clin Exp Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.3899\/jrheum.160231","article-title":"Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis.","volume":"43","author":"Tappeiner","year":"2016","journal-title":"J Rheumatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e400","DOI":"10.1111\/aos.13015","article-title":"Outcome of tocilizumab treatment in refractory ocular inflammatory diseases.","volume":"94","author":"Silpa-archa","year":"2016","journal-title":"Acta Ophthalmol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1089\/jop.2021.0098","article-title":"Current knowledge of biologics in treatment of noninfectious uveitis.","volume":"38","author":"Gupta","year":"2022","journal-title":"J Ocul Pharmacol Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.sjopt.2016.12.004","article-title":"Successful treatment of Beh\u00e7et\u2019s uveitis with Tocilizumab.","volume":"31","author":"Alokaily","year":"2017","journal-title":"Saudi J Ophthalmol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1080\/09273948.2016.1231331","article-title":"Efficacy of anti-IL6-receptor tocilizumab in refractory cystoid macular edema of birdshot retinochoroidopathy report of two cases and literature review.","volume":"25","author":"Calvo-R\u00edo","year":"2017","journal-title":"Ocul Immunol Inflamm."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/09273948.2017.1355471","article-title":"Tocilizumab for the treatment of beh\u00e7et uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy.","volume":"26","author":"Eser Ozturk","year":"2018","journal-title":"Ocul Immunol Inflamm."},{"key":"B52","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/rheumatology\/kex480","article-title":"Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Beh\u00e7et\u2019s disease: multicentre retrospective study.","volume":"57","author":"Atienza-Mateo","year":"2018","journal-title":"Rheumatol Oxf Engl."},{"key":"B53","doi-asserted-by":"publisher","first-page":"975","DOI":"10.4103\/ijo.IJO_1938_18","article-title":"Intravenous tocilizumab in idiopathic pediatric uveitis with refractory cystoid macular edema - A case report.","volume":"67","author":"Babu","year":"2019","journal-title":"Indian J Ophthalmol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/jcpt.12821","article-title":"Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: a report of two cases.","volume":"44","author":"Dipasquale","year":"2019","journal-title":"J Clin Pharm Ther."},{"key":"B55","first-page":"151","article-title":"Tocilizumab in refractory juvenile idiopathic arthritis with associated uveitis: a case report.","volume":"44","author":"Sousa-Neves","year":"2019","journal-title":"Acta Reumatol Port."},{"key":"B56","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.reuma.2018.05.001","article-title":"Scleroderma \u201cen coup de sabre\u201d with epilepsy and uveitis successfully treated with tocilizumab.","volume":"16","author":"Osminina","year":"2020","journal-title":"Reumatol Clin."},{"key":"B57","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/09273948.2020.1817501","article-title":"Tocilizumab employment in the treatment of resistant juvenile idiopathic arthritis associated uveitis.","volume":"29","author":"Maleki","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"key":"B58","doi-asserted-by":"publisher","first-page":"37","DOI":"10.55563\/clinexprheumatol\/9ipkcs","article-title":"Tocilizumab in Beh\u00e7et\u2019s disease with refractory ocular and\/or neurological involvement: response according to different clinical phenotypes.","volume":"39","author":"Atienza-Mateo","year":"2021","journal-title":"Clin Exp Rheumatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/09273948.2020.1712431","article-title":"Tocilizumab as an effective treatment option in children with refractory intermediate and panuveitis.","volume":"29","author":"Wennink","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"key":"B60","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12969-021-00514-4","article-title":"Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials.","volume":"19","author":"Welzel","year":"2021","journal-title":"Pediatr Rheumatol Online J."},{"key":"B61","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.oret.2021.08.008","article-title":"Anti-interleukin-6 antibodies for autoimmune retinopathy with macular edema.","volume":"6","author":"Deaner","year":"2022","journal-title":"Ophthalmol Retina."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/s41433-022-02315-9","article-title":"Six-month outcomes of infliximab and tocilizumab therapy in non-infectious retinal vasculitis.","volume":"37","author":"Karaca","year":"2023","journal-title":"Eye Lond Engl."},{"key":"B63","doi-asserted-by":"publisher","first-page":"885230","DOI":"10.3389\/fped.2023.885230","article-title":"Relentless placoid chorioretinitis: a review of four cases in pediatric and young adult patients with a discussion of therapeutic strategies.","volume":"11","author":"Zaheer","year":"2023","journal-title":"Front Pediatr."},{"key":"B64","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12969-023-00883-y","article-title":"Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report.","volume":"21","author":"Burlo","year":"2023","journal-title":"Pediatr Rheumatol Online J."},{"key":"B65","doi-asserted-by":"publisher","first-page":"423","DOI":"10.59249\/NQRT7239","article-title":"Tocilizumab for cystoid macular edema secondary to immune recovery uveitis in a patient with contraindications to long-term systemic corticosteroid.","volume":"97","author":"Nguyen","year":"2024","journal-title":"Yale J Biol Med."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2024.2354751","article-title":"Outcomes of intravenous tocilizumab treatment for refractory pars planitis.","author":"Kongrat","year":"2024","journal-title":"Ocul Immunol Inflamm."},{"key":"B67","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12348-024-00443-9","article-title":"Long-term effects of tocilizumab on retinal and choroidal inflammation in Birdshot uveitis.","volume":"14","author":"Zur Bonsen","year":"2024","journal-title":"J Ophthalmic Inflamm Infect."},{"key":"B68","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/09273948.2022.2126374","article-title":"Efficacy and safety of tocilizumab in the management of non-infectious uveitis failed with conventional immunomodulatory and Anti-TNF\u03b1 therapies.","volume":"32","author":"Uludag","year":"2024","journal-title":"Ocul Immunol Inflamm."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1080\/09273948.2024.2332783","article-title":"Multiple sclerosis-associated uveitis: a case report of refractory bilateral chronic granulomatous panuveitis successfully treated with tocilizumab.","volume":"32","author":"Gil","year":"2024","journal-title":"Ocul Immunol Inflamm."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1535805","DOI":"10.3389\/fopht.2025.1535805","article-title":"Case Report: ROSAH syndrome presents diagnostic and therapeutic challenges.","volume":"5","author":"Shunyakova","year":"2025","journal-title":"Front Ophthalmol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"100247","DOI":"10.1016\/j.jtauto.2024.100247","article-title":"To switch or to swap? Evidence from a meta-analysis for the best treatment approach in childhood chronic uveitis resistant to the I anti-TNF.","volume":"9","author":"Maccora","year":"2024","journal-title":"J Transl Autoimmun."},{"key":"B72","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ajo.2025.05.002","article-title":"Efficacy and safety of biologics in pediatric noninfectious retinal vasculitis.","volume":"277","author":"Karaca","year":"2025","journal-title":"Am J Ophthalmol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1007\/s00417-013-2436-y","article-title":"Tocilizumab treatment for refractory uveitis-related cystoid macular edema.","volume":"251","author":"Ad\u00e1n","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s00417-012-2243-x","article-title":"Tocilizumab treatment for recalcitrant uveitic macular edema.","volume":"251","author":"Ad\u00e1n","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1016\/j.ophtha.2014.06.050","article-title":"Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema.","volume":"121","author":"Mesquida","year":"2014","journal-title":"Ophthalmology."},{"key":"B76","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3109\/09273948.2015.1099680","article-title":"Tocilizumab in uveitic macular edema refractory to previous immunomodulatory treatment.","volume":"25","author":"Deuter","year":"2017","journal-title":"Ocul Immunol Inflamm."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1097\/IAE.0000000000001690","article-title":"Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema.","volume":"38","author":"Mesquida","year":"2018","journal-title":"Retina Phila Pa."},{"key":"B78","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10067-018-4007-4","article-title":"Tocilizumab for the treatment of birdshot uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy: two cases report and literature review.","volume":"37","author":"Leclercq","year":"2018","journal-title":"Clin Rheumatol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ajo.2018.12.019","article-title":"Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients.","volume":"200","author":"Vegas-Revenga","year":"2019","journal-title":"Am J Ophthalmol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/09273948.2019.1644350","article-title":"Subcutaneous tocilizumab for cystoid macular edema secondary to juvenile idiopathic arthritis (JIA)-associated uveitis: a case report.","volume":"29","author":"Ad\u00e1n","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"key":"B81","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ophtha.2021.11.013","article-title":"Anti-tumor necrosis factor \u03b1 versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the french uveitis network.","volume":"129","author":"Leclercq","year":"2022","journal-title":"Ophthalmology."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1097\/IAE.0000000000004177","article-title":"CYSTOID macular edema in birdshot retinochoro\u00efditis: long-term treatment study in 142 patients.","volume":"44","author":"Fardeau","year":"2024","journal-title":"retina Phila Pa."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.3390\/jcm13051402","article-title":"An observational study in the real clinical practice of the treatment of noninfectious uveitis.","volume":"13","author":"Esteban-Ortega","year":"2024","journal-title":"J Clin Med."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.oftale.2026.502508","article-title":"Tocilizumab and azathioprine in the management of refractory macular edema associated with beh\u00e7et\u2019s disease: clinical experience.","author":"JavierBarrosoP\u00e9rez","year":"2026","journal-title":"Arch Soc Espanola Oftalmol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"152153","DOI":"10.1016\/j.semarthrit.2022.152153","article-title":"Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet\u2019s disease. Multicenter study of 49 patients.","volume":"58","author":"Barroso-Garc\u00eda","year":"2023","journal-title":"Semin Arthritis Rheum."},{"key":"B86","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","article-title":"Primary (Month-6) outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis.","volume":"183","author":"Sepah","year":"2017","journal-title":"Am J Ophthalmol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40942-020-00245-w","article-title":"Posterior segment inflammatory outcomes assessed using fluorescein angiography in the STOP-UVEITIS study.","volume":"6","author":"Sadiq","year":"2020","journal-title":"Int J Retina Vitr."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/S2665-9913(20)30008-4","article-title":"Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial.","volume":"2","author":"Ramanan","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1080\/09273948.2022.2161916","article-title":"Subcutaneous tocilizumab in juvenile idiopathic arthritis associated uveitis.","volume":"31","author":"Marino","year":"2023","journal-title":"Ocul Immunol Inflamm."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/bjo-2025-327410","article-title":"Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders.","volume":"109","author":"Sota","year":"2025","journal-title":"Br J Ophthalmol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.55563\/clinexprheumatol\/xnb396","article-title":"Anti-interleukin 6 receptor antibody tocilizumab was not satisfactory for acute attack of Beh\u00e7et\u2019s uveitis in three consecutive patients.","volume":"40","author":"Zhao","year":"2022","journal-title":"Clin Exp Rheumatol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"682327","DOI":"10.3389\/fped.2021.682327","article-title":"Long term experience in patients with JIA-associated uveitis in a large referral center.","volume":"9","author":"Marelli","year":"2021","journal-title":"Front Pediatr."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e683","DOI":"10.1111\/aos.12720","article-title":"Tocilizumab and steroid boli for treatment-resistant anterior necrotizing scleritis.","volume":"93","author":"Tode","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1080\/03009742.2016.1275774","article-title":"Successful treatment with tocilizumab for refractory scleritis associated with relapsing polychondritis.","volume":"46","author":"Shimizu","year":"2017","journal-title":"Scand J Rheumatol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"8294560","DOI":"10.1155\/2020\/8294560","article-title":"New potential weapons for refractory scleritis in the era of targeted therapy.","volume":"2020","author":"Fabiani","year":"2020","journal-title":"Mediators Inflamm."},{"key":"B96","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/09273948.2019.1617885","article-title":"Successful tocilizumab treatment for scleritis.","volume":"28","author":"Poelman","year":"2020","journal-title":"Ocul Immunol Inflamm."},{"key":"B97","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/09273948.2020.1763405","article-title":"Sustained remission with tocilizumab in refractory relapsing polychondritis with ocular involvement: a case series.","volume":"29","author":"Farhat","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1136\/annrheumdis-2021-220876","article-title":"Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan.","volume":"80","author":"Kirino","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B99","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1080\/09273948.2022.2058555","article-title":"Tocilizumab in recalcitrant bilateral scleritis in a case of relapsing polychondritis: A 17-year follow up.","volume":"31","author":"Doctor","year":"2023","journal-title":"Ocul Immunol Inflamm."},{"key":"B100","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1080\/09273948.2024.2413894","article-title":"Posterior scleritis associated with late-onset takayasu arteritis: a case report.","volume":"33","author":"Bertolani","year":"2025","journal-title":"Ocul Immunol Inflamm."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2050313X251346047","DOI":"10.1177\/2050313X251346047","article-title":"The sequential therapy for non-infectious scleritis: a case report.","volume":"13","author":"Xie","year":"2025","journal-title":"SAGE Open Med Case Rep."},{"key":"B102","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3899\/jrheum.160908","article-title":"Subcutaneous tocilizumab may be less effective than intravenous tocilizumab in the treatment of juvenile idiopathic arthritis-associated uveitis.","volume":"44","author":"Quesada-Masachs","year":"2017","journal-title":"J Rheumatol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/j.jcjo.2024.06.016","article-title":"Switching from intravenous to subcutaneous tocilizumab for uveitis during the COVID-19 pandemic: a case series.","volume":"60","author":"Mohan","year":"2025","journal-title":"Can J Ophthalmol J Can Ophtalmol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ophtha.2024.10.010","article-title":"Efficacy of subcutaneous and intravenous tocilizumab in noninfectious uveitis.","volume":"132","author":"Kherani","year":"2025","journal-title":"Ophthalmology."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ophtha.2025.05.014","article-title":"Comparative effectiveness of intravenous versus subcutaneous tocilizumab for refractory uveitis: a retrospective analysis.","volume":"132","author":"Leclercq","year":"2025","journal-title":"Ophthalmology."},{"key":"B106","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12348-023-00336-3","article-title":"Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis.","volume":"13","author":"Leclercq","year":"2023","journal-title":"J Ophthalmic Inflamm Infect."},{"key":"B107","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ophtha.2018.09.044","article-title":"Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN study.","volume":"126","author":"Heissigerov\u00e1","year":"2019","journal-title":"Ophthalmology."},{"key":"B108","unstructured":"Hoffmann-La Roche. A Multi-center, Non-Randomized, Open-label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7200220 in Monotherapy and in Combination With Ranibizumab Following Intravitreal Administration in Patients With Diabetic or Uveitic Macular Edema [Clinical trial registration]. Clinical trial registration no.: NCT06771271.\n          \n          2025"},{"key":"B109","unstructured":"Results from the Phase 1 DOVETAIL Study of Anti-IL6 Monoclonal Antibody Vamikibart for Uveitic Macular Edema.\n          \n          2026"},{"key":"B110","unstructured":"Hoffmann-La Roche. A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Vamikibart Administered Intravitreally in Patients With Uveitic Macular Edema [Clinical trial registration]. Clinical trial registration no.: NCT05642312.\n          \n          2025"},{"key":"B111","unstructured":"Hoffmann-La Roche. A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Vamikibart Administered Intravitreally in Patients With Uveitic Macular Edema [Clinical trial registration]. Clinical trial registration no.: NCT05642325.\n          \n          2026"},{"key":"B112","unstructured":"Genentech: Press Releases | Friday, Oct 17, 2025.\n          \n          2025"},{"key":"B113","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.berh.2018.08.002","article-title":"Uveitis and spondyloarthropathies.","volume":"31","author":"Sharma","year":"2017","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.jaci.2007.01.010","article-title":"IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease.","volume":"119","author":"Chi","year":"2007","journal-title":"J Allergy Clin Immunol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1167\/iovs.07-1390","article-title":"Upregulated IL-23 and IL-17 in Beh\u00e7et patients with active uveitis.","volume":"49","author":"Chi","year":"2008","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B116","doi-asserted-by":"publisher","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med."},{"key":"B117","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology."},{"key":"B118","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","article-title":"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.","volume":"122","author":"Letko","year":"2015","journal-title":"Ophthalmology."},{"key":"B119","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/ceo.13922","article-title":"Secukinumab in HLA-B27 associated uveitis.","volume":"49","author":"Miserocchi","year":"2021","journal-title":"Clin Experiment Ophthalmol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1491981","DOI":"10.3389\/fopht.2025.1491981","article-title":"Secukinumab in refractory non-infectious anterior uveitis.","volume":"5","author":"Olivas-Vergara","year":"2025","journal-title":"Front Ophthalmol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"300060520969494","DOI":"10.1177\/0300060520969494","article-title":"Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report.","volume":"48","author":"Lu","year":"2020","journal-title":"J Int Med Res."},{"key":"B122","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.4103\/ijo.IJO_1081_20","article-title":"Role of secukinumab in ankylosing spondylitis with tubercular uveitis.","volume":"68","author":"Mahendradas","year":"2020","journal-title":"Indian J Ophthalmol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"e31554","DOI":"10.1097\/MD.0000000000031554","article-title":"Onset of spondyloarthritis in a patient treated with adalimumab for relapsing anterior uveitis - efficacy of secukinumab on the joint domain and on ocular inflammatory relapses: a case report.","volume":"101","author":"Raimondo","year":"2022","journal-title":"Medicine."},{"key":"B124","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1007\/s10067-025-07759-4","article-title":"Etanercept-induced sarcoidosis presenting with bilateral panuveitis: diagnostic value of ocular signs and therapeutic response to IL-17A inhibition-a case-based review.","volume":"44","author":"Bonifazi","year":"2025","journal-title":"Clin Rheumatol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1093\/rheumatology\/keae003","article-title":"Comparative risk of incident and recurrent acute anterior uveitis across different biological agents in patients with ankylosing spondylitis.","volume":"64","author":"Kwon","year":"2025","journal-title":"Rheumatol Oxf Engl."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1759720X251340255","DOI":"10.1177\/1759720X251340255","article-title":"Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab.","volume":"17","author":"Brandt-J\u00fcrgens","year":"2025","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1136\/ard-2024-225933","article-title":"Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b\/3 trials.","volume":"83","author":"Brown","year":"2024","journal-title":"Ann Rheum Dis."},{"key":"B128","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.immuni.2020.06.022","article-title":"The Cytokine IL-17A Limits Th17 pathogenicity via a negative feedback loop driven by autocrine induction of IL-24.","volume":"53","author":"Chong","year":"2020","journal-title":"Immunity."},{"key":"B129","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.4049\/jimmunol.168.11.5699","article-title":"A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R.","volume":"168","author":"Parham","year":"2002","journal-title":"J Immunol Baltim Md."},{"key":"B130","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1136\/annrheumdis-2012-202392","article-title":"Successful long-term triple disease control by ustekinumab in a patient with Behcet\u2019s disease, psoriasis and hidradenitis suppurativa.","volume":"72","author":"Baerveldt","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12527","article-title":"Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.","volume":"30","author":"Mugheddu","year":"2017","journal-title":"Dermatol Ther."},{"key":"B132","unstructured":"A Pilot Study to Investigate Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis [Clinical trial registration]. Clinical trial registration no.: NCT02911116.\n          \n          2021"},{"key":"B133","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ueg2.12094","article-title":"The impact of ustekinumab on extraintestinal manifestations of Crohn\u2019s disease: a post hoc analysis of the UNITI studies.","volume":"9","author":"Narula","year":"2021","journal-title":"United Eur Gastroenterol J."},{"key":"B134","doi-asserted-by":"publisher","first-page":"adv34206","DOI":"10.2340\/actadv.v104.34206","article-title":"Ustekinumab demonstrates lower uveitis risk in moderate to severe psoriasis patients compared with tumor necrosis factor-\u03b1 inhibitors.","volume":"104","author":"Bang","year":"2024","journal-title":"Acta Derm Venereol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects.","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs."},{"key":"B136","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","article-title":"Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn\u2019s disease and ulcerative colitis?","volume":"77","author":"Baker","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B137","doi-asserted-by":"publisher","first-page":"101380","DOI":"10.1016\/j.preteyeres.2025.101380","article-title":"Immunomodulatory therapy in non-infectious uveitis: current landscape, gaps, and future directions.","volume":"108","author":"Agrawal","year":"2025","journal-title":"Prog Retin Eye Res."},{"key":"B138","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors.","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet Lond Engl."},{"key":"B139","doi-asserted-by":"publisher","first-page":"104515","DOI":"10.1016\/j.drudis.2025.104515","article-title":"Evolving landscape of small-molecule immunotherapeutics for uveitis: a scoping review.","volume":"30","author":"Yim","year":"2025","journal-title":"Drug Discov Today."},{"key":"B140","unstructured":"A Proof-of-Concept, Randomized, Double-Masked Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Noninfectious Intermediate, Posterior, or Panuveitis (OPTYK-1) [Clinical trial registration] Clinical trial registration no.: NCT05953688.\n          \n          2024"},{"key":"B141","volume-title":"Tofacitinib. In: StatPearls.","author":"Padda","year":"2025"},{"key":"B142","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis.","volume":"13","author":"Paley","year":"2019","journal-title":"Am J Ophthalmol Case Rep."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1080\/09273948.2019.1605453","article-title":"Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis.","volume":"27","author":"Bauermann","year":"2019","journal-title":"Ocul Immunol Inflamm."},{"key":"B144","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","article-title":"JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.","volume":"39","author":"Miserocchi","year":"2020","journal-title":"Clin Rheumatol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"784860","DOI":"10.3389\/fphar.2021.784860","article-title":"Case report: a promising treatment strategy for noninfectious uveitis.","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.4103\/ijo.IJO_998_20","article-title":"Tofacitinib in Vogt-Koyanagi-Harada disease.","volume":"68","author":"Dutta Majumder","year":"2020","journal-title":"Indian J Ophthalmol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000550660","article-title":"A case of refractory panuveitis with coexisting spondyloarthritis successfully treated with tofacitinib.","volume":"17","author":"Wakabayashi","year":"2026","journal-title":"Case Rep Ophthalmol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.4103\/ijo.IJO_534_20","article-title":"Tofacitinib in recalcitrant scleritis: First case report from India.","volume":"68","author":"Pyare","year":"2020","journal-title":"Indian J Ophthalmol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/09273948.2024.2359001","article-title":"Long-term outcome of tofacitinib treatment for systemic autoimmune disease-associated refractory scleritis.","volume":"33","author":"Kim","year":"2025","journal-title":"Ocul Immunol Inflamm."},{"key":"B150","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1080\/09273948.2022.2113805","article-title":"Tofacitinib in scleritis: a case series.","volume":"32","author":"Pyare","year":"2024","journal-title":"Ocul Immunol Inflamm."},{"key":"B151","doi-asserted-by":"publisher","first-page":"367","DOI":"10.31138\/mjr.20230828.ti","article-title":"Tofacitinib in refractory scleritis: a case series.","volume":"34","author":"Dey","year":"2023","journal-title":"Mediterr J Rheumatol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1080\/09273948.2025.2532828","article-title":"Tofacitinib in ocular inflammation: experience from a tertiary eye centre in South India.","volume":"33","author":"Babu","year":"2025","journal-title":"Ocul Immunol Inflamm."},{"key":"B153","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1080\/09273948.2024.2323671","article-title":"Tofacitinib for refractory uveitis and scleritis in children: a case series.","volume":"32","author":"Dutta Majumder","year":"2024","journal-title":"Ocul Immunol Inflamm."},{"key":"B154","doi-asserted-by":"publisher","first-page":"764067","DOI":"10.3389\/fmed.2021.764067","article-title":"Effectiveness of baricitinib in refractory seronegative rheumatoid arthritis and uveitis: a case report.","volume":"8","author":"Kaneko","year":"2021","journal-title":"Front Med."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1509404","DOI":"10.3389\/fphar.2025.1509404","article-title":"Case report: Effectiveness of Janus kinase inhibitors in the management of isolated noninfectious uveitis: a case series.","volume":"16","author":"Vidic Krhlikar","year":"2025","journal-title":"Front Pharmacol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/acr.25644","article-title":"Effectiveness and safety of baricitinib for juvenile idiopathic arthritis associated uveitis or chronic anterior antinuclear antibody positive uveitis.","volume":"78","author":"Ramanan","year":"2025","journal-title":"Arthritis Care Res."},{"key":"B157","unstructured":"Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis [Clinical trial registration]. Clinical trial registration no.: NCT05651880.\n          \n          2022"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1080\/09273948.2022.2069128","article-title":"Beneficial effect of upadacitinib in an adult patient with juvenile idiopathic arthritis-associated uveitis after unsatisfactory response to tofacitinib: a case report.","volume":"31","author":"Baquet-Walscheid","year":"2023","journal-title":"Ocul Immunol Inflamm."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1080\/09273948.2023.2263557","article-title":"Successful remission with upadacitinib in two patients with anti-TNF-refractory macular edema associated with Beh\u00e7et\u2019s uveitis.","volume":"32","author":"Tao","year":"2024","journal-title":"Ocul Immunol Inflamm."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18502\/jovr.v20.14952","article-title":"Successful use of upadacitinib, a selective JAK inhibitor, in the treatment of two cases of recalcitrant chronic uveitis.","volume":"20","author":"Dominguez","year":"2025","journal-title":"J Ophthalmic Vis Res."},{"key":"B161","doi-asserted-by":"publisher","first-page":"591","DOI":"10.55563\/clinexprheumatol\/ot85sk","article-title":"Successful use of upadacitinib in a 14-year-old patient with juvenile idiopathic arthritis-associated uveitis and hidradenitis suppurativa.","volume":"2","author":"Romano","year":"2025","journal-title":"Clin Exp Rheumatol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1080\/09273948.2025.2519852","article-title":"Therapeutic potential of upadacitinib in adolescents with idiopathic chronic panuveitis who lost response to adalimumab.","volume":"33","author":"Guo","year":"2025","journal-title":"Ocul Immunol Inflamm."},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2025.2588918","article-title":"Successful treatment of tofacitinib-refractory scleritis associated with multiple systemic inflammatory diseases using upadacitinib.","author":"Yuge","year":"2025","journal-title":"Immunol Med."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12348-026-00580-3","article-title":"Necrotizing scleritis resistant to biologics successfully managed with the JAK inhibitor upadacitinib: a case report.","volume":"16","author":"Oyama","year":"2026","journal-title":"J Ophthalmic Inflamm Infect."},{"key":"B165","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41433-025-04065-w","article-title":"The use of Janus kinase inhibitors to treat noninfectious uveitis.","volume":"40","author":"Beckman","year":"2025","journal-title":"Eye Lond Engl."},{"key":"B166","doi-asserted-by":"publisher","first-page":"1439338","DOI":"10.3389\/fmed.2024.1439338","article-title":"Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries.","volume":"11","author":"Vitale","year":"2024","journal-title":"Front Med."},{"key":"B167","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamaophthalmol.2024.2439","article-title":"Filgotinib in active noninfectious uveitis: the HUMBOLDT randomized clinical trial.","volume":"142","author":"Srivastava","year":"2024","journal-title":"JAMA Ophthalmol."},{"key":"B168","unstructured":"Hutton\n              D.\n            \n          \n          Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in Non-Infectious Uveitis | Ophthalmology Times - Clinical Insights for Eye Specialists [Internet].\n          \n          2025"},{"key":"B169","unstructured":"Therapeutics\n              P.\n            \n          \n          Priovant Therapeutics Announces Positive Phase 2 NEPTUNE Study Results for Brepocitinib in Non-Infectious Uveitis (NIU), Showing Strongest Efficacy Data in NIU Observed to Date [Internet].\n          \n          2025"},{"key":"B170","unstructured":"A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis [Clinical trial registration]. Clinical trial registration no.: NCT06431373.\n          \n          2024"},{"key":"B171","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/ibd\/izaa289","article-title":"Tofacitinib treatment safety in moderate to severe ulcerative colitis: comparison of observational population cohort data from the IBM MarketScan\u00a7administrative claims database with tofacitinib trial data.","volume":"27","author":"Curtis","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"B172","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1002\/art.39761","article-title":"Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments.","volume":"68","author":"Xie","year":"2016","journal-title":"Arthritis Rheumatol Hoboken NJ."},{"key":"B173","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s40264-020-00958-9","article-title":"Thromboembolic safety reporting of tofacitinib and baricitinib: an analysis of the WHO vigibase.","volume":"43","author":"Vallejo-Yag\u00fce","year":"2020","journal-title":"Drug Saf."},{"key":"B174","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B175","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci Rep."},{"key":"B176","doi-asserted-by":"publisher","first-page":"1189389","DOI":"10.3389\/fphar.2023.1189389","article-title":"Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis.","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in routine care patients with rheumatoid arthritis (STAR-RA) study.","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B178","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/ard-2023-224017","article-title":"Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies.","volume":"82","author":"Reinisch","year":"2023","journal-title":"Ann Rheum Dis."},{"key":"B179","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/ICB.0000000000001626","article-title":"Cytomegalovirus retinitis in non-hiv immunocompromised individuals on tofacitinib for rheumatoid arthritis.","volume":"19","author":"Smith","year":"2025","journal-title":"Retin Cases Brief Rep."},{"key":"B180","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1093\/rheumatology\/kez681","article-title":"Tofacitinib-associated cytomegalovirus retinitis.","volume":"59","author":"Cugley","year":"2020","journal-title":"Rheumatology."},{"key":"B181","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jiac.2017.03.002","article-title":"Cytomegalovirus retinitis followed by immune recovery uveitis in an elderly patient with rheumatoid arthritis undergoing administration of methotrexate and tofacitinib combination therapy.","volume":"23","author":"Yanagisawa","year":"2017","journal-title":"J Infect Chemother."},{"key":"B182","doi-asserted-by":"publisher","first-page":"e48337","DOI":"10.7759\/cureus.48337","article-title":"Cytomegalovirus retinitis in a patient taking upadacitinib: a case report.","volume":"15","author":"Hirai","year":"2023","journal-title":"Cureus."},{"key":"B183","doi-asserted-by":"publisher","first-page":"1673970","DOI":"10.3389\/fimmu.2025.1673970","article-title":"Comparative risk of uveitis with Janus kinase inhibitors versus tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic diseases: a target trial emulation study.","volume":"16","author":"Bai","year":"2025","journal-title":"Front Immunol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1016\/j.bmcl.2005.07.053","article-title":"species specificity, and cellular activity of cyclopentene dicarboxylic acid amides as DHODH inhibitors.","volume":"15","author":"Leban","year":"2005","journal-title":"Bioorg Med Chem Lett."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1023224","DOI":"10.3389\/fmed.2022.1023224","article-title":"A new small molecule DHODH-inhibitor [KIO-100 (PP-001)] targeting activated T cells for intraocular treatment of uveitis - A phase I clinical trial.","volume":"9","author":"Thurau","year":"2022","journal-title":"Front Med."},{"key":"B186","unstructured":"A Phase 2, Open-label, Multiple Dose Study of the Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema (KLARITY-1) [Clinical trial registration] Clinical Trial Registration no.: NCT06825702.\n          \n          2025"},{"key":"B187","unstructured":"Pharma\n              T.\n            \n          \n          Tarsier Pharma Announces Results from a Phase 3 Clinical trial in Subjects with Noninfectious Anterior Uveitis Including Subjects with Uveitic Glaucoma [Internet].\n          \n          2025"},{"key":"B188","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ajo.2025.12.034","article-title":"Dazdotuftide: novel treatment for non-infectious uveitis with superior intraocular pressure safety profile: a randomized clinical trial.","volume":"284","author":"Chu","year":"2026","journal-title":"Am J Ophthalmol."},{"key":"B189","unstructured":"Pharma\n              T.\n            \n          \n          Tarsier Pharma Receives FDA Agreement Under Special Protocol Assessment (SPA) for Tarsier-04 Phase 3 Trial of TRS01 Ophthalmic Solution for the Treatment of Non-infectious Uveitis including Uveitic Glaucoma.\n          \n          2025"},{"key":"B190","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1089\/jop.2020.0056","article-title":"Randomized phase 2 trial of reproxalap, a novel reactive aldehyde species inhibitor, in patients with noninfectious anterior uveitis: model for corticosteroid replacement.","volume":"36","author":"Mandell","year":"2020","journal-title":"J Ocul Pharmacol Ther."},{"key":"B191","unstructured":"A Phase 3, Randomized, Double-Masked, Vehicle-controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis. Clinical Trial Registration no.: NCT03131154.\n          \n          2025"},{"key":"B192","unstructured":"Aldeyra Therapeutics Announces Results from the SOLACE Trial in Noninfectious Anterior Uveitis | Aldeyra Therapeutics, Inc.\n          \n          2025"},{"key":"B193","unstructured":"Aldeyra to Stop Noninfectious Anterior Uveitis Program.\n          \n          2025"},{"key":"B194","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2147\/TCRM.S148586","article-title":"Current treatment options for psoriatic arthritis: spotlight on abatacept.","volume":"14","author":"Ursini","year":"2018","journal-title":"Ther Clin Risk Manag."},{"key":"B195","first-page":"1897","article-title":"Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report.","volume":"35","author":"Angeles-Han","year":"2008","journal-title":"J Rheumatol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/acr.20359","article-title":"Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al.","volume":"63","author":"Elhai","year":"2011","journal-title":"Arthritis Care Res."},{"key":"B197","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00417-010-1523-6","article-title":"Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis.","volume":"249","author":"Kenawy","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol."},{"key":"B198","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.3390\/biomedicines10082041","article-title":"Juvenile idiopathic arthritis, uveitis and multiple sclerosis: description of two patients and literature review.","volume":"10","author":"Chighizola","year":"2022","journal-title":"Biomedicines."},{"key":"B199","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00417-015-3140-x","article-title":"Long-term efficacy of abatacept in pediatric patients with idiopathic uveitis: a case series.","volume":"253","author":"Marrani","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/acr.20115","article-title":"Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis.","volume":"62","author":"Zulian","year":"2010","journal-title":"Arthritis Care Res."},{"key":"B201","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3899\/jrheum.151389","article-title":"Comparable efficacy of abatacept used as first-line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis.","volume":"43","author":"Birolo","year":"2016","journal-title":"J Rheumatol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1136\/bjo-2022-321585","article-title":"Efficacy and safety of abatacept to treat active birdshot uveitis: a prospective open label interventional proof-of-concept trial.","volume":"108","author":"Schauwvlieghe","year":"2024","journal-title":"Br J Ophthalmol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jamaophthalmol.2016.1013","article-title":"Assessment of CTLA-4 deficiency-related autoimmune choroidopathy response to abatacept.","volume":"134","author":"Shields","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"B204","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1080\/09273948.2025.2504576","article-title":"Partial response to abatacept for bilateral asymmetrical intermediate uveitis in CTLA-4 haploinsufficiency.","volume":"33","author":"Khalil","year":"2025","journal-title":"Ocul Immunol Inflamm."},{"key":"B205","unstructured":"Suhler\n              E.\n            \n          \n          An Openlabel, Phase II Trial of Abatacept (Orencia) in the Treatment of Refractory Non-infectious Uveitis. Clinical trial registration no.: NCT01279954.\n          \n          2019"},{"key":"B206","doi-asserted-by":"publisher","first-page":"851453","DOI":"10.3389\/fped.2022.851453","article-title":"Tocilizumab and abatacept for the treatment of childhood chronic uveitis: a monocentric comparison experience.","volume":"10","author":"Maccora","year":"2022","journal-title":"Front Pediatr."},{"key":"B207","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000103239","article-title":"Rituximab as a treatment option for refractory endogenous anterior uveitis.","volume":"39","author":"Tappeiner","year":"2007","journal-title":"Ophthalmic Res."},{"key":"B208","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12348-011-0027-9","article-title":"Rituximab in refractory Vogt-Koyanagi-Harada disease.","volume":"1","author":"Dolz-Marco","year":"2011","journal-title":"J Ophthalmic Inflamm Infect."},{"key":"B209","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s10067-014-2781-1","article-title":"Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease.","volume":"34","author":"Caso","year":"2015","journal-title":"Clin Rheumatol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3109\/14397595.2015.1071234","article-title":"Rituximab for sight-threatening refractory pediatric Vogt-Koyanagi-Harada disease.","volume":"28","author":"Umran","year":"2018","journal-title":"Mod Rheumatol."},{"key":"B211","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1080\/09273948.2022.2161917","article-title":"Reversal of peripheral iris depigmentation associated with Vogt-Koyanagi-Harada disease.","volume":"32","author":"Tobaigy","year":"2024","journal-title":"Ocul Immunol Inflamm."},{"key":"B212","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1080\/09273948.2021.1880604","article-title":"Efficacy of rituximab treatment in Vogt-Koyanagi-Harada disease poorly controlled by traditional immunosuppressive treatment.","volume":"30","author":"Bolletta","year":"2022","journal-title":"Ocul Immunol Inflamm."},{"key":"B213","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1080\/09273948.2020.1820531","article-title":"Efficacy of B cell depletion therapy with rituximab in refractory chronic recurrent uveitis associated with Vogt-Koyanagi-Harada disease.","volume":"30","author":"Abu El-Asrar","year":"2022","journal-title":"Ocul Immunol Inflamm."},{"key":"B214","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12348-025-00522-5","article-title":"Safety and efficacy of rituximab in refractory noninfectious uveitis and scleritis.","volume":"15","author":"Al Ghulaiga","year":"2025","journal-title":"J Ophthalmic Inflamm Infect."},{"key":"B215","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1093\/rheumatology\/ker107","article-title":"Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab).","volume":"50","author":"Heiligenhaus","year":"2011","journal-title":"Rheumatology."},{"key":"B216","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.autrev.2011.07.001","article-title":"Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases.","volume":"11","author":"Miserocchi","year":"2011","journal-title":"Autoimmun Rev."},{"key":"B217","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1136\/bjophthalmol-2015-306790","article-title":"Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis.","volume":"100","author":"Miserocchi","year":"2016","journal-title":"Br J Ophthalmol."},{"key":"B218","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s10165-008-0057-9","article-title":"Treatment of retinal vasculitis in Beh\u00e7et\u2019s disease with rituximab.","volume":"18","author":"Sadreddini","year":"2008","journal-title":"Mod Rheumatol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet\u2019s disease; randomized single-blind control study (pilot study).","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int J Rheum Dis."},{"key":"B220","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.4103\/ijo.IJO_2017_19","article-title":"Uveitis, retinal vasculitis, and loss of accommodation as sole manifestations of demyelinating disease: a case report.","volume":"68","author":"Babu","year":"2020","journal-title":"Indian J Ophthalmol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1111\/ene.15453","article-title":"Anti-CD20 therapy for multiple sclerosis-associated uveitis: a case series.","volume":"29","author":"Stascheit","year":"2022","journal-title":"Eur J Neurol."},{"key":"B222","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/09273948.2023.2236211","article-title":"Uveitis in the setting of co-existing systemic sarcoidosis and multiple sclerosis.","volume":"32","author":"Gnanaraj","year":"2024","journal-title":"Ocul Immunol Inflamm."},{"key":"B223","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.4103\/ijo.IJO_966_20","article-title":"Biological therapy in refractory cases of uveitis and scleritis: an analysis of 18 cases from a tertiary eye care center from South India.","volume":"68","author":"Sadhu","year":"2020","journal-title":"Indian J Ophthalmol."},{"key":"B224","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ajo.2017.12.004","article-title":"Characteristics and visual outcome of refractory retinal vasculitis associated with antineutrophil cytoplasm antibody-associated vasculitides.","volume":"187","author":"Lin","year":"2018","journal-title":"Am J Ophthalmol."},{"key":"B225","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/IAE.0000000000001563","article-title":"Long-Term outcomes of rituximab therapy in patients with noninfectious posterior uveitis refractory to conventional immunosuppressive therapy.","volume":"38","author":"Lasave","year":"2018","journal-title":"Retina."},{"key":"B226","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3899\/jrheum.130206","article-title":"Experiences with rituximab for the treatment of autoimmune diseases with ocular involvement.","volume":"41","author":"Pelegrin","year":"2014","journal-title":"J Rheumatol."},{"key":"B227","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/0961203309347332","article-title":"Bilateral retinal vasculitis in a patient with systemic lupus erythematosus and its remission with rituximab therapy.","volume":"19","author":"Hickman","year":"2010","journal-title":"Lupus."},{"key":"B228","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/bjophthalmol-2013-304686","article-title":"Treatment of diffuse subretinal fibrosis uveitis with rituximab.","volume":"99","author":"Cornish","year":"2015","journal-title":"Br J Ophthalmol."},{"key":"B229","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.2147\/OPTH.S35521","article-title":"Rituximab for refractory granulomatous eye disease.","volume":"6","author":"Lower","year":"2012","journal-title":"Clin Ophthalmol."},{"key":"B230","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000351426","article-title":"Can rituximab induce long-term disease remission in patients with intra-ocular non-infectious inflammation?","volume":"230","author":"Tomkins-Netzer","year":"2013","journal-title":"Ophthalmol J Int Ophtalmol Int J Ophthalmol Z Augenheilkd."},{"key":"B231","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1869-5760-3-56","article-title":"Anterior uveitis secondary to type II essential cryoglobulinemia.","volume":"3","author":"Nicholson","year":"2013","journal-title":"J Ophthalmic Inflamm Infect."},{"key":"B232","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2025.2519869","article-title":"Paradoxical exacerbation of birdshot retinochoroiditis following rituximab.","volume":"18","author":"Patel","year":"2025","journal-title":"Ocul Immunol Inflamm."},{"key":"B233","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ophtha.2003.05.036","article-title":"Waldenstr\u00f6m\u2019s macroglobulinemia-associated retinopathy.","volume":"111","author":"Sen","year":"2004","journal-title":"Ophthalmology."},{"key":"B234","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3109\/09273941003802379","article-title":"A case of autoimmune retinopathy associated with thyroid carcinoma.","volume":"18","author":"Mahdi","year":"2010","journal-title":"Ocul Immunol Inflamm."},{"key":"B235","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/j.jcjo.2012.11.010","article-title":"Intravenous rituximab for the treatment of cancer-associated retinopathy.","volume":"48","author":"Or","year":"2013","journal-title":"Can J Ophthalmol J Can Ophtalmol."},{"key":"B236","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.6004\/jnccn.2013.0156","article-title":"Treatment of cancer-associated retinopathy with rituximab.","volume":"11","author":"Dy","year":"2013","journal-title":"J Natl Compr Cancer Netw JNCCN."},{"key":"B237","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1016\/j.jcjo.2015.08.009","article-title":"Rituximab treatment for nonparaneoplastic autoimmune retinopathy.","volume":"50","author":"Fox","year":"2015","journal-title":"Can J Ophthalmol J Can Ophtalmol."},{"key":"B238","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ajoc.2016.03.007","article-title":"Electroretinographic improvement after rituximab therapy in a patient with autoimmune retinopathy.","volume":"2","author":"Uludag","year":"2016","journal-title":"Am J Ophthalmol Case Rep."},{"key":"B239","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2147\/OPTH.S120162","article-title":"Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy.","volume":"11","author":"Maleki","year":"2017","journal-title":"Clin Ophthalmol."},{"key":"B240","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13023-017-0680-7","article-title":"Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy.","volume":"12","author":"Boudreault","year":"2017","journal-title":"Orphanet J Rare Dis."},{"key":"B241","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ajo.2017.04.019","article-title":"Outcomes in autoimmune retinopathy patients treated with rituximab.","volume":"180","author":"Davoudi","year":"2017","journal-title":"Am J Ophthalmol."},{"key":"B242","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12348-019-0171-1","article-title":"Non-paraneoplastic autoimmune retinopathy: multimodal testing characteristics of 13 cases.","volume":"9","author":"Khanna","year":"2019","journal-title":"J Ophthalmic Inflamm Infect."},{"key":"B243","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1080\/09273948.2019.1636094","article-title":"Combination treatment with rituximab and bortezomib in a patient with non-paraneoplastic autoimmune retinopathy.","volume":"28","author":"Benson","year":"2020","journal-title":"Ocul Immunol Inflamm."},{"key":"B244","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12886-020-01423-y","article-title":"Autoimmune retinopathy associated with monoclonal gammopathy of undetermined significance: a case report.","volume":"20","author":"Eton","year":"2020","journal-title":"BMC Ophthalmol."},{"key":"B245","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4103\/tjo.tjo_32_20","article-title":"Rituximab for autoimmune retinopathy: results of a phase I\/II clinical trial.","volume":"11","author":"Armbrust","year":"2021","journal-title":"Taiwan J Ophthalmol."},{"key":"B246","doi-asserted-by":"publisher","first-page":"515","DOI":"10.18502\/jovr.v17i4.12304","article-title":"Rituximab monotherapy versus rituximab and bortezomib combination therapy for treatment of non-paraneoplastic autoimmune retinopathy.","volume":"17","author":"Maleki","year":"2022","journal-title":"J Ophthalmic Vis Res."},{"key":"B247","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1136\/bjo.2005.075689","article-title":"Successful treatment of Wegener\u2019s granulomatosis associated scleritis with rituximab.","volume":"89","author":"Cheung","year":"2005","journal-title":"Br J Ophthalmol."},{"key":"B248","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1136\/bjo.2006.113316","article-title":"Rituximab treatment for peripheral ulcerative keratitis associated with Wegener\u2019s granulomatosis.","volume":"91","author":"Freidlin","year":"2007","journal-title":"Br J Ophthalmol."},{"key":"B249","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1080\/09273940802331643","article-title":"Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener\u2019s granulomatosis.","volume":"16","author":"Onal","year":"2008","journal-title":"Ocul Immunol Inflamm."},{"key":"B250","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24454","article-title":"Rituximab is effective in the treatment of refractory ophthalmic Wegener\u2019s granulomatosis.","volume":"60","author":"Taylor","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B251","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00417-015-3198-5","article-title":"Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener\u2019s).","volume":"253","author":"Recillas-Gispert","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B252","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1080\/09273948.2017.1327602","article-title":"Rituximab induction and maintenance treatment in patients with scleritis and granulomatosis with polyangiitis (Wegener\u2019s).","volume":"26","author":"You","year":"2018","journal-title":"Ocul Immunol Inflamm."},{"key":"B253","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4103\/injr.injr_83_18","article-title":"Use of biologic response modifiers for the management of ocular inflammatory conditions.","volume":"13","author":"Rivera-Grana","year":"2018","journal-title":"Indian J Rheumatol."},{"key":"B254","doi-asserted-by":"publisher","first-page":"8","DOI":"10.17659\/01.2020.0003","article-title":"Rituximab induced increased intraocular pressure in recalcitrant scleritis.","volume":"10","author":"Mohanty","year":"2020","journal-title":"J Case Rep."},{"key":"B255","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000486791","article-title":"Cyclophosphamide or rituximab treatment of scleritis and uveitis for patients with granulomatosis with polyangiitis.","volume":"61","author":"Ahmed","year":"2019","journal-title":"Ophthalmic Res."},{"key":"B256","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.4103\/ijo.IJO_2249_19","article-title":"Rituximab therapy combined with methotrexate for severe necrotizing scleritis in a case of granulomatosis with polyangiitis.","volume":"68","author":"Murthy","year":"2020","journal-title":"Indian J Ophthalmol."},{"key":"B257","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4103\/ijo.IJO_1411_22","article-title":"Clinical profile and management of granulomatosis with polyangiitis\u2013associated scleritis from a tertiary care hospital in South India.","volume":"71","author":"Mohanan-Earatt","year":"2023","journal-title":"Indian J Ophthalmol."},{"key":"B258","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1159\/000530007","article-title":"Granulomatosis with polyangiitis complicated by severe exudative retinal detachment and orbital granuloma successfully controlled with rituximab: a case report.","volume":"14","author":"Sugisawa","year":"2023","journal-title":"Case Rep Ophthalmol."},{"key":"B259","doi-asserted-by":"publisher","first-page":"358","DOI":"10.4274\/tjo.galenos.2024.72317","article-title":"Management of orbital granulomatous polyangiitis presenting with lacrimal gland involvement: treatment of subsequent peripheral ulcerative keratitis, anterior uveitis, and exudative retinal detachment in a challenging case.","volume":"54","author":"Oklar","year":"2024","journal-title":"Turk J Ophthalmol."},{"key":"B260","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.ophtha.2015.01.016","article-title":"Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: impact on localized and nonlocalized disease.","volume":"122","author":"Joshi","year":"2015","journal-title":"Ophthalmology."},{"key":"B261","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.4103\/ijo.IJO_1644_20","article-title":"Worsening of posterior scleritis and orbital pseudotumor in a patient with granulomatosis polyangiitis with rituximab-A case report.","volume":"68","author":"Babu","year":"2020","journal-title":"Indian J Ophthalmol."},{"key":"B262","first-page":"90","article-title":"Macular oedema following rituximab infusion in two patients with Wegener\u2019s granulomatosis.","volume":"28","author":"Bussone","year":"2010","journal-title":"Clin Exp Rheumatol."},{"key":"B263","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000342842","article-title":"Combined infliximab and rituximab in necrotising scleritis.","volume":"3","author":"Morarji","year":"2012","journal-title":"Case Rep Ophthalmol."},{"key":"B264","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1016\/j.jcjo.2018.12.004","article-title":"Ocular and orbital exacerbation after rituximab therapy for granulomatosis with polyangiitis.","volume":"54","author":"Shih","year":"2019","journal-title":"Can J Ophthalmol J Can Ophtalmol."},{"key":"B265","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/ICB.0000000000001484","article-title":"Paradoxical exacerbation of sclerouveitis after rituximab infusion.","volume":"18","author":"Vergouwen","year":"2024","journal-title":"Retin Cases Brief Rep."},{"key":"B266","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1136\/bjo.2007.133173","article-title":"Rituximab for treatment of ocular inflammatory disease: a series of four cases.","volume":"93","author":"Kurz","year":"2009","journal-title":"Br J Ophthalmol."},{"key":"B267","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1136\/bjo.2008.147157","article-title":"Rituximab for treatment of scleritis associated with rheumatoid arthritis.","volume":"93","author":"Chauhan","year":"2009","journal-title":"Br J Ophthalmol."},{"key":"B268","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/09273941003739928","article-title":"Rituximab treatment for persistent scleritis associated with rheumatoid arthritis.","volume":"18","author":"Iaccheri","year":"2010","journal-title":"Ocul Immunol Inflamm."},{"key":"B269","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ajo.2016.03.037","article-title":"Rituximab in the treatment of refractory noninfectious scleritis.","volume":"166","author":"Cao","year":"2016","journal-title":"Am J Ophthalmol."},{"key":"B270","doi-asserted-by":"publisher","first-page":"e861","DOI":"10.1111\/aos.14939","article-title":"Efficacy and maintenance of rituximab treatment in non-infectious scleritis.","volume":"100","author":"Vergouwen","year":"2022","journal-title":"Acta Ophthalmol."},{"key":"B271","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1080\/09273948.2023.2229900","article-title":"Long-term follow-up of patients with scleritis after rituximab treatment including B cell monitoring.","volume":"32","author":"van Bilsen","year":"2024","journal-title":"Ocul Immunol Inflamm."},{"key":"B272","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1136\/ard.2004.027128","article-title":"Successful treatment of refractory anterior scleritis in primary Sjogren\u2019s syndrome with rituximab.","volume":"64","author":"Ahmadi-Simab","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"B273","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jbspin.2013.07.011","article-title":"Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis.","volume":"81","author":"Caso","year":"2014","journal-title":"Joint Bone Spine."},{"key":"B274","doi-asserted-by":"publisher","first-page":"339","DOI":"10.5935\/0004-2749.20160097","article-title":"Management of necrotizing scleritis after pterygium surgery with rituximab.","volume":"79","author":"Fidelix","year":"2016","journal-title":"Arq Bras Oftalmol."},{"key":"B275","doi-asserted-by":"publisher","first-page":"101333","DOI":"10.1016\/j.ajoc.2022.101333","article-title":"Posterior scleritis with anti-neutrophil cytoplasmic antibody-associated vasculitis utilizing rituximab therapy to maintain remission: a case report.","volume":"25","author":"Weng","year":"2022","journal-title":"Am J Ophthalmol Case Rep."},{"key":"B276","doi-asserted-by":"publisher","first-page":"e7595","DOI":"10.1002\/ccr3.7595","article-title":"ANCA-associated vasculitis with scleritis, corneal melt, and perforation rescued by rituximab: case report and literature review.","volume":"11","author":"Matsuo","year":"2023","journal-title":"Clin Case Rep."},{"key":"B277","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12886-025-04027-6","article-title":"Isolated ANCA-associated scleritis successfully treated with systemic rituximab; a case report and review of literature.","volume":"25","author":"Tahavvori","year":"2025","journal-title":"BMC Ophthalmol."},{"key":"B278","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/j.ophtha.2014.04.044","article-title":"Rituximab therapy for refractory scleritis: results of a phase I\/II dose-ranging, randomized, clinical trial.","volume":"121","author":"Suhler","year":"2014","journal-title":"Ophthalmology."},{"key":"B279","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1080\/09273948.2022.2029498","article-title":"Subconjunctival rituximab administration for the treatment of scleritis.","volume":"30","author":"Vergouwen","year":"2022","journal-title":"Ocul Immunol Inflamm."},{"key":"B280","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/j.1755-3768.2011.02127.x","article-title":"Fatal Pneumocystis jirovecii pneumonia following immunosuppressive therapy with rituximab and prednisolone for posterior scleritis.","volume":"90","author":"Stilling-Vinther","year":"2012","journal-title":"Acta Ophthalmol."},{"key":"B281","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3109\/09273948.2014.999377","article-title":"Rituximab and acute retinal necrosis in a patient with scleromalacia and rheumatoid arthritis.","volume":"24","author":"Schuler","year":"2016","journal-title":"Ocul Immunol Inflamm."},{"key":"B282","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","article-title":"Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study.","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol."},{"key":"B283","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/ecco-jcc\/jjz167","article-title":"Two cases of successful ustekinumab treatment for non-infectious uveitis associated with Crohn\u2019s disease.","volume":"14","author":"Chateau","year":"2020","journal-title":"J Crohns Colitis."},{"key":"B284","doi-asserted-by":"publisher","first-page":"N118","DOI":"10.1177\/1120672120981874","article-title":"Long term follow-up and effect of immunosuppression in acute zonal occult outer retinopathy.","volume":"32","author":"Guijarro","year":"2020","journal-title":"Eur J Ophthalmol."},{"key":"B285","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3899\/jrheum.140410","article-title":"Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis.","volume":"42","author":"Tappeiner","year":"2015","journal-title":"J Rheumatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1846374\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:43:21Z","timestamp":1778823801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1846374\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":285,"alternative-id":["10.3389\/fmed.2026.1846374"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1846374","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"article-number":"1846374"}}